Our results support that HRR deficiency provides the basis of PARP inhibition sensitivity in vivo and is frequent among tumors without germline mutations in BRCA1/2 genes, in line with the frequency of HRD genomic signature among breast cancer patients (Davies et al, 2017). Here, PARP1 is linked to breast cancer.